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Abstract
Introduction Postischemic injury to the coronary vascular
endothelium, in particular to the endothelial glycocalyx, may
provoke fluid extravasation. Shedding of the glycocalyx is
triggered by redox stress encountered during reperfusion and
should be alleviated by the radical scavenger nitric oxide (NO).
The objective of this study was to investigate the effect of
exogenous administration of NO during reperfusion on both
coronary endothelial glycocalyx and vascular integrity.
Methods Isolated guinea pig hearts were subjected to 15
minutes of warm global ischemia followed by 20 minutes of
reperfusion in the absence (Control group) and presence (NO
group) of 4 μM NO. In further experiments, the endothelial
glycocalyx was enzymatically degraded by means of heparinase
followed by reperfusion without (HEP  group) and with NO
(HEP+NO group).
Results Ischemia and reperfusion severely damaged the
endothelial glycocalyx. Shedding of heparan sulfate and damage
assessed by electron microscopy were less in the presence of
NO. Compared with baseline, coronary fluid extravasation
increased after ischemia in the Control, HEP, and HEP+NO
groups but remained almost unchanged in the NO group. Tissue
edema was significantly attenuated in this group. Coronary
vascular resistance rose by 25% to 30% during reperfusion, but
not when NO was applied, irrespective of the state of the
glycocalyx. Acute postischemic myocardial release of lactate
was comparable in the four groups, whereas release of adenine
nucleotide catabolites was reduced 42% by NO. The coronary
venous level of uric acid, a potent antioxidant and scavenger of
peroxynitrite, paradoxically decreased during postischemic
infusion of NO.
Conclusion The cardioprotective effect of NO in postischemic
reperfusion includes prevention of coronary vascular leak and
interstitial edema and a tendency to forestall both no-reflow and
degradation of the endothelial glycocalyx.
Introduction
Myocardial damage and coronary microvascular dysfunction,
including the no-reflow phenomenon and edema formation,
evolve from coronary occlusion and consecutive reperfusion.
These are relatively common clinical occurrences, for example,
in conjunction with percutaneous coronary angioplasty
(PTCA), coronary artery bypass grafting (CABG), and heart
transplant reperfusion [1]. Over the past 20 years, major
advances have been made toward understanding the role of
nitric oxide (NO) in the ischemic biology of the heart and it has
become clear that NO, either endogenous or exogenous, rep-
resents one of the most important defenses against myocar-
dial ischemia and reperfusion injury. The influence of NO on
microvascular permeability is less clear because conflicting
results exist in the literature [2,3].
A healthy vascular endothelium is coated by extracellular
domains of a large variety of membrane-bound molecules that,
together, constitute the glycocalyx. In vivo, the glycocalyx
binds plasma proteins, forming the endothelial surface layer.
This zone has a thickness of 400 to 500 nm in microvessels
(in some regions, it is even thicker than the endothelial cells
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themselves) and is an integral part of the circulation. Various
experimental models showed this large structure to be funda-
mentally involved in numerous physiological and pathophysio-
logical actions in the circulation. Loss of coronary glycocalyx
integrity is accompanied by leakage of fluid from the vascular
compartment, resulting in swelling of the pericapillary intersti-
tial space [4-6]. Moreover, it is recognized that the endothelial
glycocalyx is especially prone to injury during ischemia/reper-
fusion [4,7,8]. Very recently, damage of the endothelial glyco-
calyx could be demonstrated in patients undergoing global or
regional ischemia during vascular surgery [9]. Perturbation of
the glycocalyx also results in adhesion of platelets and leuko-
cytes to the capillary and venular endothelial surface [10,11].
Furthermore, coronary dilatation induced by shear stress also
depends on an intact endothelial glycocalyx [12]. Based on
these findings, there is little doubt that degradation of the
endothelial glycocalyx leads to impaired regulation of organ
blood flow, to activation of coagulatory and inflammatory path-
ways, and to tissue edema. Investigating strategies for protect-
ing the endothelial glycocalyx against disruption obviously is
an important topic for research.
Postischemic injury appears to depend substantially on the
increased production of oxygen-derived free radicals upon
reoxygenation. Redox stress may activate proteases, espe-
cially metalloproteases. Also, redox stress associated with
ischemia/reperfusion induces mast cell degranulation, liberat-
ing tryptase and heparanase activity [13]. Activation and liber-
ation of such enzymes will undoubtedly mediate disruption of
the endothelial glycocalyx. Thus, by acting as a radical scaven-
ger, NO administered in small amounts during reperfusion
might help to protect the endothelium.
Given the established facts above, the present study investi-
gated the effect of exogenous NO, given at the time of reper-
fusion, on the functional and metabolic outcome following
myocardial ischemia/reperfusion, particularly with regard to
the state of the endothelial glycocalyx. All experiments were
conducted on an intact vascular bed, namely the coronary sys-
tem of isolated perfused hearts (guinea pig Langendorff prep-
arations), with a highly standardized protocol of ischemia and
reperfusion. The impact of exogenous administration of NO (4
μM) was investigated by measuring coronary vascular resist-
ance and net fluid filtration with and without enzymatic degra-
dation of the glycocalyx by means of application of heparinase.
The rationale for using heparinase is that it has proven to be
specific for shedding heparan sulfates and that these struc-
tures comprise the greatest portion of the luminal endothelial
glycocalyx [14]. The state of the glycocalyx was assessed by
electron and light microscopy. The metabolic influence of NO
was examined by measuring myocardial release of lactate,
catabolism of adenine nucleotides, and degradation of the
endogenous antioxidant uric acid during reperfusion.
Materials and methods
This investigation conforms with the Guide for the Care and
Use of Laboratory Animals [15]. Licensure and approval of the
investigation were obtained from the Government of Upper
Bavaria (file no. 209.1/211-2531.3-3/99).
Heart preparation
In brief, guinea pigs (male; weight 250 to 300 g) were stunned
by neck dislocation with a specially designed instrument, and,
immediately after the opening of the thorax, the hearts were
arrested with ice-cold isotonic saline. Quickly, the aorta was
cannulated and the coronaries were perfused in situ at a con-
stant flow rate of 6.0 mL/minute with a modified Krebs-Hense-
leit buffer (116 mM NaCl, 23 mM NaHCO3, 3.6 mM KCl, 1.16
mM KH2PO4, 1.2 mM CaCl2, 0.58 mM MgSO4, 5.4 mM glu-
cose, 0.3 mM pyruvate, and 2.8 U/L insulin) oxygenated with
94.5% O2 and 5.5% CO2 at 37°C, pH 7.40 ± 0.05. Hearts
were removed from the thorax and prepared especially for
quantifying net coronary fluid leak as described previously
[5,6,16,17]. The hearts were not inverted and beat spontane-
ously. Such hearts are not readily suited for determining con-
tractile function. Coronary perfusion pressure in the aortic feed
line was registered online (pressure transducer; Seeheim-
Ober Beerbach, Engelsbach, Germany). Coronary venous
effluent was collected from the pulmonary artery, cannulated
and ending with a slightly negative hydrostatic pressure to pre-
clude coronary venous congestion. Interstitial and lymphatic
fluids formed by net filtration appeared at the epicardial sur-
face and dripped off the apex of the heart. This so-called tran-
sudate was collected at 1-minute intervals and quantified by
weighing on a precision scale. This value was subsequently
divided by the ventricular wet weight (w.w.) so that the unit of
transudate formation is expressed as milliliter per minute per
gram of w.w. Samples of effluent and transudate were then
immediately frozen.
Infusion lines were inserted into the aortic feed line just above
the coronary ostia to infuse small aliquots of a saturated aque-
ous solution of NO (see below) or of heparinase type-1
enzyme (Sigma-Aldrich, St. Louis, MO, USA). We have
recently shown by electron microscopy, immunohistological
staining, and quantitative measurement of constituent parts of
the glycocalyx that this enzyme selectively sheds heparan sul-
fate from the endothelial glycocalyx [14]. Enzymograms
(PAGE, gelatine) showed that heparinase had no collagenase
activity versus control, excluding enzyme activity, for example,
against the basement membrane. Constant-flow instead of
constant-pressure perfusion was chosen for the current exper-
imental model to guarantee constant levels of infused sub-
stances. The protocol allowed infusion of NO stock solution
calculated to yield an arterial infusate concentration of 4 μM.
Control experiments
The heart preparations were first characterized without
ischemia. Time control experiments were performed to evalu-Available online http://ccforum.com/content/12/3/R73
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ate the influence of 15-minute equilibration and 20-minute per-
fusion without ischemia on coronary perfusion pressure and
on transudate formation (TimeControl group). Moreover, time-
matched control values were measured after 20-minute
administration of 4 μM NO (NOControl group) and after 15-
minute application of 10 U of heparinase (HepControl group).
The results are presented in Table 1. NO infused in this man-
ner did not elicit vasodilatation; the threshold value required to
do so was approximately 10 μM (nominal arterial infusate con-
centration). The application of heparinase caused a measura-
ble increase in transudate formation.
Experimental protocols
Hearts were randomly assigned among the experimental
groups. Figure 1 illustrates the protocols applied to four
groups of hearts. The standard condition was that of constant
coronary flow perfusion (6.0 mL/minute) at 37°C. After an
equilibration period of 15 minutes, hearts were subjected to
15 minutes of global, normothermic, stopped-flow ischemia
and then reperfused under the same condition as before
ischemia. To maintain the temperature of the preparation dur-
ing ischemia, hearts were immersed in warm Tyrode's buffer
(37°C). Hearts were reperfused in the absence of NO (Figure
1, Control group), in the presence of 4 μM NO (NO group),
and after the glycocalyx had been enzymatically degraded by
means of heparinase (10 U of enzyme in a volume of 1.5 mL
applied into the coronaries in the course of the 15-minute
ischemic phase), both without NO (HEP group) or with 4 μM
NO (HEP+NO group). Samples of transudate and coronary
effluent were taken at baseline and during reperfusion. At the
end of each experiment, hearts were removed from the per-
fusion system and the atria and large vessels cut away. Excess
surface and intraventricular fluid was swabbed off and the ven-
tricles weighed at once.
Table 1
Control experiments without ischemia
TimeControl (n = 5) NOControl (n = 5) HEPControl (n = 6)
Coronary perfusion pressure, percentage 114 ± 7 89 ± 4 119 ± 5
Transudate formation, percentage 128 ± 17 99 ± 14 260 ± 14a
Values are presented as a percentage of basal and as mean ± standard deviation. The groups are as defined in Materials and methods. aP < 0.05, 
intragroup difference versus basal.
Figure 1
Experimental protocols Experimental protocols. After heart preparation and an equilibration period of 15 minutes, hearts were subjected to 15 minutes of global normother-
mic ischemia followed by 20 minutes of reperfusion. Hearts were reperfused in the absence (Control group) and presence (NO group) of 4 μM nitric 
oxide. In two further series, the glycocalyx was enzymatically degraded by heparinase, applied into the coronary system in the course of ischemia, fol-
lowed again by reperfusion in the absence (HEP group) and presence (HEP+NO group) of 4 μM NO. Transudate and coronary effluent were quan-
tified at baseline (B) (just before ischemia) and at 1, 2, 3, 4, 5, 8, 15, and 20 minutes of reperfusion. HEP, heparinase.Critical Care    Vol 12 No 3    Bruegger et al.
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Preparing and applying NO stock solution
To prepare an aqueous saturated solution of NO, 3 mL of
deionized water was sealed into a small glass vial with a stop-
per and a long syringe needle was inserted, extending almost
to the base of the vial. An additional shorter needle that did not
immerse into the solution was inserted and acted as a pres-
sure relief. After the system was purged with argon (Linde AG,
Munich, Germany) for a period of 30 minutes at a moderate
flow rate, the system was bubbled for 30 minutes with pure
NO (Linde AG). Subsequently, the needles were removed and
the rubber stopper sealed spontaneously. Just before the
experiment, this solution was transferred under exclusion of
oxygen into a glass syringe equipped with a long metal can-
nula. The concentration of NO resulting from saturation at
20°C is approximately 1.91 mM.
Quantification of tissue edema
At the end of each protocol, tissue edema was assessed by
measuring ventricular wet weight (at once) and dry weight
(after 24 hours of drying at 60°C). The quotient 'wet weight/
dry weight' was then calculated.
Determination of release of lactate, purines, and uric 
acid
Coronary venous effluent of the Control and NO groups was
collected via the pulmonary artery, and aliquots were stored (-
20°C) until analyzed. The concentration of lactate was deter-
mined by high-performance liquid chromatography (HPLC) in
aliquots acidified (pH 2.0) with perchloric acid [18]. The total
concentrations of the purines adenosine, inosine, hypoxan-
thine, xanthine, guanosine, and urate together (products of
adenine nucleotide catabolism) as well as that of uric acid
alone were quantified by reverse-phase HPLC [19]. In each
case, the concentration value, multiplied by the coronary flow
rate and divided by the ventricular w.w., yielded the respective
rate of cardiac release per gram of heart weight. The cumula-
tive release of purines was established over the first 15 min-
utes of reperfusion by calculating an area under the curve
using the trapezoidal method (Sigma plot; SPSS Inc., Chi-
cago, IL, USA).
Determination of heparan sulfate
After 15 minutes of ischemia, samples of effluent were col-
lected at 5, 8, 15, and 20 minutes during reperfusion and were
used for assessing shedding of heparan sulfate. To aggravate
the ischemia/reperfusion injury, additional hearts were sub-
jected to 20 minutes of ischemia followed by 40 minutes of
reperfusion. All samples were preconcentrated over 10-kDa
cutoff membrane filters (Millipore, Eschborn, Germany). Con-
centrations were determined with an enzyme-linked immuno-
sorbent assay (Seikagaku Corporation, Tokyo, Japan). The
cumulative release was established by calculating an area
under the curve (see above).
Light microscopy and immunohistochemistry
Hearts were perfusion-fixed after minimal perfusion (<1
minute), after 15 minutes of ischemia followed by 20 minutes
of reperfusion in the absence and presence of NO, and after
the glycocalyx had been enzymatically degraded by means of
heparinase in the course of the ischemic phase. Fixation
occurred by the addition of formaldehyde to the flowing Krebs-
Henseleit buffer to a resulting concentration of 1%. After 4
minutes, the hearts were removed from the apparatus and
stored in 4% formaldehyde solution for 24 hours. Paraffin sec-
tions (5 μm) were immunohistochemically stained with mono-
clonal antibody against heparan sulfate (Seikagaku
Corporation). The primary antibody, applied to generate an avi-
din-biotin horseradish peroxidase complex with the Vectastain
kit (Vector Laboratories, Burlingame, CA, USA), was diluted
and handled as follows: anti-heparan sulfate 1:100, tissue pre-
incubation with 0.2% trypsin at 37°C. Controls in which the
primary antibody was replaced with buffer were treated identi-
cally. Diaminobenzidine or aminoethylcarbazole was used as
chromogen.
Electron microscopy
Electron microscopy, performed in modification of Vogel and
colleagues [20], was based on in situ stabilization of the gly-
cocalyx by intracoronary application of a fixative containing lan-
thanum ions and glutaraldehyde [5,6,16,17].
Statistical analysis
Because the measured data were distributed normally (deter-
mined by Kolmogorov-Smirnov test), these are presented as
mean ± standard deviation unless otherwise indicated. Com-
parisons were made using analysis of variance for repeated
measurements. Post hoc testing was performed using the Stu-
dent-Newman-Keuls method for multiple comparisons. A P
value of less than 0.05 was considered to be significant.
Results
The effect of ischemia and reperfusion on coronary perfusion
pressure is shown in Figure 2 for all experimental groups. In
the Control and HEP groups, the data reveal that a transient
postischemic vasodilatation (decrease in coronary perfusion
pressure) tended to develop approximately 5 minutes after the
end of ischemia. This was followed by vasoconstriction
(increase in coronary perfusion pressure). After 20 minutes of
reperfusion, coronary perfusion pressure had increased signif-
icantly versus baseline in the Control group. In the presence
of 4 μM NO (NO and HEP+NO groups), this latter increase in
coronary perfusion pressure did not occur. Although there
were no significant intergroup differences after 20 minutes,
there was a significantly lower coronary resistance for all
hearts with NO as compared with those without (P < 0.05,
pooled data, n = 10 and 11, respectively). Pertinently, coro-
nary resistance did not increase within the first 5 minutes when
the infusion of NO was terminated after 20 minutes (resultsAvailable online http://ccforum.com/content/12/3/R73
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not shown). Thus, there was no acute and direct dilatatory
effect of NO.
Postischemic changes in transudate formation (that is, of net
fluid filtration in the intact coronary bed of isolated guinea pig
hearts) are illustrated in Figure 3 for all experimental groups.
Baseline transudate formation – about 20 to 50 μL/minute per
gram of w.w. – did not differ significantly among the four
groups. Postischemically, there was an increase in transudate
formation in the Control, HEP, and HEP+NO  groups with
respect to the individual group baseline (Δ = +50, +85, and
+44 μL/minute per gram of w.w. after 20 minutes, respec-
tively). In contrast, when shedding of heparan sulfate had not
been enzymatically induced prior to reperfusion (see below),
transudate formation remained almost unchanged when 4 μM
NO was applied during reperfusion (Δ = -13 μL/minute per
gram of w.w. after 20 minutes) and was significantly lower than
in the Control group at all times of reperfusion (Figure 3). Inter-
estingly, no correlation was found between transudate forma-
tion and coronary perfusion pressure (R2 = 0.016; n = 189,
pooled values of 21 hearts at 9 measuring time points each),
also demonstrating that changes in transudate formation were
not the result of any putative acute vasodilatatory effect of NO.
Mean wet-to-dry weight ratios of the isolated heart prepara-
tions determined at the end of each experimental protocol are
listed in Table 2. The mean ratios for hearts of Control, HEP,
and HEP+NO groups ranged from 7.9 to 8.3. NO applied to group) yielded a mean ratio of 6.9, indicating a significant
decrease in tissue edema formation.
Metabolic data were determined in the absence (Control
group) and presence (NO group) of 4 μM NO. The release of
purine compounds in the coronary effluent serves as a
quantitative measure of adenine nucleotide catabolism in the
heart and is illustrated in Figure 4a. A beneficial effect of NO
was observed: acute postischemic release of purines was
reduced in its presence and cumulative purine release during
reperfusion was almost halved (Control group: area under the
curve = 1,907 ± 517 nmol per gram of w.w.; NO group: area
under the curve = 1,097 ± 427 nmol per gram of w.w.; P <
0.05, n = 6 and 5, respectively). This effect exceeded by far a
decrease in the net amount of urate released from these
hearts: postischemic release of uric acid (Figure 4b) paralleled
that of total purines in the Control group, increasing more than
eightfold during early reperfusion. However, it accounted for
only about 10% of the total release of purines in the Control
group. In the presence of NO, urate decreased significantly to
only a few percent of the total purine release throughout. Lac-
tate release (Figure 4c) increased more than 10-fold during
early reperfusion in both the Control and NO groups and was
not significantly changed by the presence of NO during the
subsequent reperfusion. There was no difference in the cumu-
lative release of lactate (area under the curve) between both
groups.
Figure 2
Effect of ischemia/reperfusion on coronary perfusion pressure Effect of ischemia/reperfusion on coronary perfusion pressure. Groups 
are as defined in the legend of Figure 1. Values are presented as mean 
± standard error of the mean. *P < 0.05, intragroup difference versus 
basal (B).
Figure 3
Effect of ischemia/reperfusion on coronary transudate formation Effect of ischemia/reperfusion on coronary transudate formation. The 
groups are as defined in the legend of Figure 1. Values are presented 
as mean ± standard error of the mean. *P < 0.05, intragroup difference 
versus basal (B); #P < 0.05, intergroup difference versus the Control 
group. w.w., wet weight.Critical Care    Vol 12 No 3    Bruegger et al.
Page 6 of 11
(page number not for citation purposes)
Light microscopy after immunohistochemical staining of
nonischemic hearts evidenced heparan sulfate as a compo-
nent of the endothelial glycocalyx (Figures 5a and 5b, respec-
tively). In hearts subjected to ischemia and reperfusion without
NO, the staining of the endothelial cell lining was markedly
reduced (Figures 5c and 5d, respectively). In hearts that were
reperfused after the glycocalyx had been enzymatically
degraded by means of heparinase, no heparan sulfate was
detected at the endothelial cell lining (Figures 5e and 5f,
respectively). Hearts reperfused in the presence of NO
showed some positive staining for heparan sulfate after 20
minutes of reperfusion (Figures 5g and 5h, respectively). Inter-
estingly, the walls of the vasculature also contained heparan
sulfate.
Material immunopositive for heparan sulfate was detected in
the coronary effluent of the isolated perfused hearts and a pos-
tischemic increase was observed after 15 minutes of ischemia
(Figure 6a). There was a tendency toward a lower cumulative
release of heparan sulfate during reperfusion in the presence
of NO but this lacked statistical significance. However, extend-
ing the ischemic period to 20 minutes followed by 40 minutes
of reperfusion showed a significantly lower cumulative release
of heparan sulfate during reperfusion in the presence of NO.
Exemplary electron microscopic images illustrating coronary
vessels of the isolated guinea pig hearts are shown in Figure 7.
In comparison with a nonischemic heart, where an endothelial
glycocalyx of approximately 200- to 300-nm thickness was
found in the coronary vasculature, hearts subjected to ischemia
and reperfusion showed a dramatic loss of the endothelial sur-
face lining and strong edema formation (Figures 7a and 7b,
respectively). Hearts that had received NO during reperfusion
exhibited less edema, but the glycocalyx still showed partial
denudation (Figure 7c). Hearts pretreated with heparinase dur-
ing ischemia were completely denuded, irrespective of the
Table 2
Quantification of tissue edema
Group Wet weight/dry weight
Control experiments
TimeControl (n = 5) 7.0 ± 0.7
NOControl (n = 5) 7.0 ± 0.6
HEPControl (n = 6) 8.5 ± 0.6
Experimental groups
Control (n = 6) 8.0 ± 0.3
NO (n = 5) 6.9 ± 0.2a
HEP (n = 5) 8.3 ± 0.6
HEP+NO (n = 5) 7.9 ± 0.6
Values are presented as mean ± standard deviation. aP < 0.05 with 
respect to Control, HEP, and HEP+NO groups.
Figure 4
Coronary venous release of metabolites during the first 15 minutes of  myocardial reperfusion Coronary venous release of metabolites during the first 15 minutes of 
myocardial reperfusion. (a) Release of purines. (b) Release of urate. (c) 
Release of lactate. Hearts were reperfused in the absence (Control 
group) and presence (NO group) of 4 μM nitric oxide. Values are pre-
sented as mean ± standard error of the mean. *P < 0.05, intragroup dif-
ference versus basal (B); #P < 0.05, intergroup difference versus the 
Control group. w.w., wet weight.Available online http://ccforum.com/content/12/3/R73
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presence of NO during reperfusion (Figures 7d and 7e,
respectively).
Discussion
The major findings of this study are that NO, applied with the
onset of reoxygenation, protects isolated hearts against some
facets of postischemic reperfusion injury and that this protec-
tive effect seems to extend to the endothelial glycocalyx in the
coronary vascular bed. The evidence provided by this investi-
gation is the following:
1. Coronary resistance tended to increase during reperfusion,
but not if NO was applied. This effect seemed to be main-
tained even if the glycocalyx had been degraded beforehand.
Figure 5
Immunostaining of microvessels of guinea pig hearts with monoclonal  antibody against heparan sulfate after minimal perfusion (a, b), after 15  minutes of ischemia followed by 20 minutes of reperfusion in the  absence (c, d) and presence (g, h) of nitric oxide, and after the glyco- calyx had been enzymatically degraded by means of heparinase (e, f) Immunostaining of microvessels of guinea pig hearts with monoclonal 
antibody against heparan sulfate after minimal perfusion (a, b), after 15 
minutes of ischemia followed by 20 minutes of reperfusion in the 
absence (c, d) and presence (g, h) of nitric oxide, and after the glyco-
calyx had been enzymatically degraded by means of heparinase (e, f). 
Specimens are paraffin-embedded sections of guinea pig heart. Origi-
nal magnifications: × 20 (lefthand panels) and × 100 (righthand pan-
els). HS, heparan sulfate; VL, vascular lumen.
Figure 6
Heparan sulfate release in coronary venous effluent Heparan sulfate release in coronary venous effluent. (a) Absolute 
release of heparan sulfate in hearts subjected to 15 minutes of 
ischemia followed by 20 minutes of reperfusion. (b) Cumulative release 
of heparan sulfate in hearts subjected to 15 minutes of ischemia fol-
lowed by 20 minutes of reperfusion (15' + 20') and in hearts subjected 
to 20 minutes of ischemia followed by 40 minutes of reperfusion (20' + 
40'). Hearts were reperfused in the absence (Control group) and pres-
ence (NO group) of 4 μM nitric oxide. Values are presented as mean ± 
standard error of the mean. #P < 0.05, intergroup difference versus the 
Control group. AUC, area under the curve; B, baseline; w.w., wet 
weight.Critical Care    Vol 12 No 3    Bruegger et al.
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2. Fluid extravasation in the coronary system was increased
after ischemia, but not if NO was applied during reperfusion.
The postischemic increase in tissue edema was alleviated if
hearts were reperfused in the presence of NO. NO had no
preventive effect on coronary leak or edema if the endothelial
glycocalyx was degraded beforehand.
3. NO attenuated shedding of the endothelial glycocalyx, as
judged by enzyme-linked immunosorbent assay and electron
microscopy.
4. Metabolic stress was mitigated during reperfusion with NO,
as evidenced by a significantly lowered catabolism of high-
energy adenine nucleotides.
The observed trends in change of coronary perfusion pressure
comply with the no-reflow phenomenon and may be explained
in part by the changing absolute availability of endogenous NO
during reperfusion. The concentration of endogenous NO in
the coronary effluent, about 0.2 μM during normoperfusion
[21,22], increases again from zero during early reperfusion
[23]. However, with prolongation of reperfusion, NO synthase
activity decreases and NO is also consumed by reaction with
superoxide and hydroxyl radicals. Thus, NO decreases below
baseline values [22]. These expected changes in NO concen-
tration parallel the changes in coronary perfusion pressure
observed in the present study: hearts reperfused in the
absence of NO (Control and HEP groups) showed an inter-
mittent decrease in coronary perfusion pressure followed by
an increase. Such an increase did not occur in hearts reper-
fused with exogenous NO (NO  and  HEP+NO  groups),
although NO applied into the arterial perfusate at this level (4
μM) did not per se elicit coronary dilatation. Since coronary
perfusion pressure directly reflects coronary resistance under
conditions of constant coronary flow as used here, it seems
that moderate amounts of exogenous NO (see below) may be
able to compensate the increase in vascular tone caused by
depletion of endogenous NO in reperfused hearts. However,
alternative actions, not directed immediately toward the vascu-
lar smooth muscle, also need to be considered. One such
possibility would be alleviation of interstitial edema (that is, of
extramural compression). This was found only for the NO and
not for the HEP+NO hearts, suggesting that interstitial pres-
sure was not a major determinant of coronary resistance.
Despite the seemingly good concordance of effect and expec-
tation concerning NO levels, the actual magnitudes of the cor-
onary resistance changes seen in the present study were
definitely limited. Thus, the action of NO in this respect should
not be overstated.
A far stronger action was evident concerning vascular leak. In
the isolated perfused heart model, changes in transmural fluid
passage in the entire coronary bed can be assessed directly
by determining the flow of transudate. This fluid, which
appears on the epicardial surface, may be regarded as a mix-
ture of interstitial and lymphatic liquid and its flow is equal to
net fluid filtration in the coronary system. The basal value of up
to 50 μL/minute per gram of w.w. obtained in the present
study compared favorably with that reported by others
[24,25], as did the observed postischemic increase. The
endothelial glycocalyx plays a major role in the development of
postischemic coronary vascular leak [8,26] and, together with
the endothelial cells themselves, constitutes the vascular 'dou-
ble barrier' against fluid extravasation [16,17].
Bulk permeability of water and small hydrophilic solutes is
basically influenced by the Starling forces of intravasal and
extravasal hydrostatic and oncotic pressures and by the vas-
cular barrier. The only variable force in our model was the cor-
onary perfusion pressure. However, there was certainly no
consistent relationship between coronary perfusion pressure
and transudate formation in the four groups of hearts
(compare Figures 2 and 3). Thus, the observed differences of
net fluid transport across the vascular wall at any one time
Figure 7
Exemplary electron microscopic images of hearts without ischemia (a)  and hearts subjected to 15 minutes of warm ischemia and 20 minutes  of reperfusion without nitric oxide (NO) (b) (Control group) and with 4  μM exogenous NO (c) (NO group) Exemplary electron microscopic images of hearts without ischemia (a) 
and hearts subjected to 15 minutes of warm ischemia and 20 minutes 
of reperfusion without nitric oxide (NO) (b) (Control group) and with 4 
μM exogenous NO (c) (NO group). The glycocalyx of 200 to 300 nm in 
width normally present in all vessels has virtually disappeared after 
ischemia and reperfusion in the absence of NO and edema has devel-
oped. NO partly mitigated these effects. The effect of heparinase is 
shown in (d) (HEP group) and (e) (HEP+NO group). EG, endothelial 
glycocalyx; IS, interstitial space; M, cardiomyocytes; VL, vascular 
lumen.Available online http://ccforum.com/content/12/3/R73
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must reflect differences in hydraulic conductivity (that is, in the
integrity of the double barrier composed of the endothelial gly-
cocalyx and the endothelial cells). When the glycocalyx is
damaged, vascular permeability increases. This was seen in
hearts treated with heparinase (Table 1: HEPControl; Figure 2:
HEP and HEP+NO groups). The elevated formation of transu-
date after 15 minutes of ischemia in hearts not treated with
heparinase (Control group) supports the view that ischemia/
reperfusion damaged the glycocalyx. In agreement with the
assumption that NO alleviated degradation of the coronary
endothelial glycocalyx, there was less leak and less heparan
sulfate-reactive material tended to appear in the coronary efflu-
ent of those hearts reperfused solely with 4 μM NO. Electron
microscopic visualization of the microvasculature in control
hearts and hearts subjected to ischemia/reperfusion without
and with NO corroborated the partial protection of the
endothelial glycocalyx by exogenous NO (Figure 7).
There has been an ongoing debate in the literature as to
whether NO is a protectant or a source of injury in the reper-
fused heart, but it has clearly been demonstrated that NO has
infarct-sparing abilities in isolated buffer-perfused hearts [27].
In line with the results of the present study, various drugs (for
example, statins, angiotensin-converting enzyme inhibitors,
angiotensin-receptor blockers, nitrates, and nitrites) have pro-
duced beneficial effects in experimental models of ischemia/
reperfusion via the enhancement of NO bioavailability [28].
Cardioprotection by inhalational NO has not been conclusively
demonstrated in humans. However, the NO donor
nitroprusside improved coronary flow and myocardial pump
function in patients undergoing elective PTCA [29] and
CABG [30,31], respectively.
The metabolic data also indicate further protective actions of
NO in the isolated guinea pig hearts. The release of purines
has been shown to be a sensitive and accurate index of energy
metabolism [32]: purine release increases whenever energy
production is impaired or inadequate to meet demand and
decreases if energy balance is restored. It may be postulated
that NO mitigates energy demand resulting from oxidative
stress (for example, the familiar postischemic dysregulation of
cytosolic ion levels). Irrespectively, the observed preservation
of purines in hearts reperfused with NO will serve to restore
and/or maintain levels of adenine nucleotides and high-energy
phosphates because de novo synthesis of purines – the only
alternative to salvage – is an energetically very costly process.
In contrast, washout of lactate did not differ between the Con-
trol and NO groups. Thus, direct ischemic stress was compa-
rable in the two groups and, as was to be expected, is
uninfluenced by NO applied afterwards. This result is in full
accord with the study postulate.
Microvascular permeability induced by ischemia/reperfusion in
the dog heart was reduced by antioxidants and radical scaven-
gers [33]. A protective effect of NO could reside in an
enhanced scavenging of reactive oxygen species, particularly
hydroxyl and superoxide radicals. Indirect evidence for such an
effect of NO can be derived from the substantially lower con-
centration of uric acid found in the effluent of hearts reper-
fused with NO. Uric acid reacts avidly with peroxynitrite
formed by reaction of NO with superoxide [18]. The enhanced
formation of urate due to nucleotide catabolism in hearts sub-
jected to ischemia/reperfusion (see Control group) actually
provides more endogenous antioxidant to mitigate the removal
of peroxynitrite. It should be kept in mind that humans have
exceptionally high blood urate levels [34]. The generation of
physiological antioxidants such as urate in complete biological
systems allows NO to alleviate postischemic redox stress
without giving rise to toxic products [19,34]. Although the data
certainly show a change in the stress to hearts of the NO
group as opposed to the Control group (compatible with a
scavenging of radicals and reactive oxidative species), the
metabolic effects seen in these hearts could also arise from G-
protein- and c-GMP-induced actions or from other cellular
effects of NO [27,28].
A critique of the experimental model used here should address
the likely partial oxidation of NO applied into an oxygenated
Krebs-Henseleit perfusate. Although the time of contact from
the site of infusion to entry into the coronary system is only
about 0.2 seconds, some of the NO will react with oxygen to
form toxic nitrogen dioxide (NO2) and higher oxides. A similar
fate befalls NO applied via the respiratory tract in human ther-
apy. Like peroxynitrite, NO2 reacts with urate. Thus, part of the
marked decrease in coronary urate levels seen in our perfusion
protocol upon application of NO may well reflect oxidative
degradation due to inactivation of NO2. Owing to the high
plasma levels of urate in humans, the same detoxification may
be expected when NO is used clinically, explaining its relative
safety in human use [35].
We had deliberated extensively on alternative routes and
sources of NO before deciding on the application of physically
dissolved, pure NO. A major drawback of chemical generators
of NO, such as NO-penicillamine, S-nitrosoglutathione, and
SIN-1, is that only the rate of generation of NO can be pre-
dicted, but not the actual concentration in the solution being
acutely applied, as hydrolysis to NO and oxidation of NO are
occurring from the moment water is added to compose the
respective stock solutions. On the other hand, the concentra-
tion of NO in a saturated aqueous solution at room tempera-
ture and normal atmospheric pressure is well characterized in
the literature. Moreover, the choice of direct NO generators in
clinical use is neither very great nor tempting.
Action on the combined barrier formed by the glycocalyx and
the endothelial cell bodies is better assessed in the presence
of colloidal substances [6]. Colloids are able to establish an
oncotic gradient at the endothelial surface, opposing fluid fil-Critical Care    Vol 12 No 3    Bruegger et al.
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tration [17]. However, postischemic application of hydroxye-
thyl starch alone to the perfusate already prevented much of
the increase in coronary leak that developed during reper-
fusion [36].
Because the isolated hearts are perfused with blood-free
Krebs-Henseleit buffer solution, the endothelial cells are
presumably covered only by membrane-anchored molecules.
That is, the glycocalyx in its strictest sense, and not the
endothelial surface layer, is under investigation. It is also
impossible to assess aspects of ischemia/reperfusion injuries
that may be initiated and influenced by plasma-borne factors
and formed constituents of blood. On the other hand, physio-
logic antioxidants of plasma are absent, perhaps accentuating
damage by reactive oxygen species. Inhalational NO has been
shown to be beneficial after myocardial infarction [37], but no
link was drawn to the glycocalyx. This is quite understandable
because it is not easy to directly visualize the glycocalyx in
vivo. Thus, in vitro models are still required.
Conclusion
In summary, the present study shows a protective role for NO
during myocardial reperfusion. The cardioprotective effect of
NO in ischemia/reperfusion includes attenuation of the coro-
nary no-reflow phenomenon and prevention of coronary vascu-
lar leak and tissue edema. The latter actions are based on
preservation of the endothelial glycocalyx.
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